Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a good week for Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) shareholders, because the company has just released its latest second-quarter results, and the shares gained 4.7% to US$4.42. Revenues fell badly short of expectations, with revenue of US$88k being some 26% below what the analysts had forecast. Statutory losses were in line with forecasts, with Orchestra BioMed Holdings losing US$0.38 a share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the current consensus, from the seven analysts covering Orchestra BioMed Holdings, is for revenues of US$445.9k in 2026. This implies a painful 99% reduction in Orchestra BioMed Holdings' revenue over the past 12 months. Per-share losses are expected to explode, reaching US$1.53 per share. Before this earnings announcement, the analysts had been modelling revenues of US$469.7k and losses of US$1.50 per share in 2026. Overall it looks as though the analysts are negative in this update. Although revenue forecasts held steady, the consensus also made a modest increase to to its losses per share forecasts.
View our latest analysis for Orchestra BioMed Holdings
There was no major change to the consensus price target of US$12.33, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Orchestra BioMed Holdings analyst has a price target of US$20.00 per share, while the most pessimistic values it at US$9.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that revenue is expected to reverse, with a forecast 100% annualised decline to the end of 2026. That is a notable change from historical growth of 98% over the last three years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 7.6% per year. It's pretty clear that Orchestra BioMed Holdings' revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Orchestra BioMed Holdings. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$12.33, with the latest estimates not enough to have an impact on their price targets.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Orchestra BioMed Holdings analysts - going out to 2028, and you can see them free on our platform here.
You still need to take note of risks, for example - Orchestra BioMed Holdings has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.